SREBF1 and metabolic dysfunction-associated steatotic liver disease: A reduction in liver miR‐155 may contribute to hepatic lipogenesis since one of its transcriptional targets, SREBP1, an activator of fatty acid synthesis, is increased in liver from patients with MASLD [29].